|
DE102005023170A1
(de)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimierte Formulierung für mRNA
|
|
US7947286B2
(en)
|
2005-10-07 |
2011-05-24 |
Panthera Biopharma Llc |
Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
|
|
CA2733104C
(en)
*
|
2008-08-07 |
2015-07-14 |
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health |
Optimized promoter sequence
|
|
US9526777B2
(en)
*
|
2010-04-16 |
2016-12-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
|
|
DK2655604T3
(en)
|
2010-12-14 |
2018-08-06 |
Us Gov Health & Human Services |
ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
|
|
EP3896759A1
(en)
|
2011-10-05 |
2021-10-20 |
OneD Material, Inc. |
Silicon nanostructure active materials for lithium ion batteries and processes, compositions, components, and devices related thereto
|
|
CA3194125A1
(en)
*
|
2012-04-12 |
2013-10-17 |
The Trustees Of The University Of Pennsylvania |
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
|
|
JP2016513115A
(ja)
*
|
2013-02-21 |
2016-05-12 |
チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド |
ワクチン組成物
|
|
BR112016029579A2
(pt)
|
2014-06-26 |
2017-08-22 |
Janssen Vaccines & Prevention Bv |
anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
|
|
ZA201608812B
(en)
|
2014-06-26 |
2019-08-28 |
Janssen Vaccines & Prevention Bv |
Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
|
|
PT3188753T
(pt)
|
2014-09-03 |
2020-03-25 |
Bavarian Nordic As |
Métodos e composições para induzir imunidade protetora contra infeção por filovírus
|
|
CA2960096A1
(en)
|
2014-09-03 |
2016-03-10 |
Bavarian Nordic A/S |
Methods and compositions for enhancing immune responses
|
|
EP3188752A2
(en)
*
|
2014-09-03 |
2017-07-12 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
EP3233113A1
(en)
*
|
2014-12-16 |
2017-10-25 |
CureVac AG |
Ebolavirus and marburgvirus vaccines
|
|
GB201502209D0
(en)
|
2015-02-10 |
2015-03-25 |
Sec Dep For Health The And Chancellor Masters And Scholars Of The University Of Oxford The And Micro |
Filovirus therapy
|
|
WO2016138312A2
(en)
*
|
2015-02-25 |
2016-09-01 |
Vanderbilt University |
Antibody-mediated neutralization of marburg virus
|
|
US11135280B2
(en)
*
|
2016-03-28 |
2021-10-05 |
Integrated Biotherapeutics, Inc. |
Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
|
|
WO2018011198A1
(en)
|
2016-07-15 |
2018-01-18 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
EP3484507A1
(en)
|
2016-07-15 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
EP3606553A1
(en)
|
2017-04-06 |
2020-02-12 |
Janssen Vaccines & Prevention B.V. |
Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
|
|
CA3107083A1
(en)
*
|
2018-08-13 |
2020-02-20 |
Janssen Vaccines & Prevention B.V. |
Stabilized filovirus glycoprotein trimers
|
|
WO2022226060A1
(en)
*
|
2021-04-21 |
2022-10-27 |
Vanderbilt University |
Antibody cocktail for treatment of ebolavirus infections
|